1.12
1.12 (0%)
As of Feb 14, 2025
Scynexis Inc [SCYX]
Source:
Company Overview
Scynexis, Inc. is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections. We are developing our proprietary antifungal platform “fungerps”, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a broad range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and most common mucorales species.
| Country | United States |
| Headquarters | jersey city, new jersey |
| Phone Number | (201) 884-5485 |
| Industry | manufacturing |
| CEO | David Angulo, M.D. |
| Website | www.scynexis.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $3.7 |
| Operating Profit | $-37.1 |
| Net Income | $-21.3 |
| Net Cash | $-18 |
Profit Ratios
| Gross Margin | $3.7 |
| Operating Margin | -990.8 |
| Profit as % of Revenues | -17.6% |
| Profit as % of Assets | -19.4% |
| Profit as % of Stockholder Equity | -38.7% |
Management Effectiveness
| Return on Equity | -38.7% |
| Return on Assets | -23.5% |
| Turnover Ratio | 3.4% |
| EBITA | $-37.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $90.6 |
| Total Liabilities | $35.6 |
| Operating Cash Flow | $-24 |
| Investing Cash Flow | $6.2 |
| Financing Cash Flow | $-0.1 |
